Yuriy Abramov is a Senior Principal Scientist at Pfizer Inc. with 15 years of experience in computational sciences in Drug Discovery and Development. He has a proven track record for developing new ideas and approaches from the concept stage to successful implementation. His current interests include but not limited to computational pharmaceutical solid state chemistry.
Nikolay Dokholyan, PhD, MS
Thomas Passananti Professor and Vice Chair for Research, Department of Pharmacology
Thomas Passananti Professor, Department of Biochemistry & Molecular Biology
Scientific Program: Experimental Therapeutics
Dr. Dokholyan is the Vice Chair for Research, Departments of Pharmacology and Biochemistry & Molecular Biology at Penn State College of Medicine. The mission of his lab is to develop and apply integrated computational and experimental strategies to understand, sense and control misfolded proteins in order to uncover the etiologies of human neurodegenerative diseases and develop therapeutics to fight them.
Sean has over 23 years experience in pharmaceutical drug discovery. He graduated from the University of Aberdeen; receiving his M.Sc., Ph.D. in Clinical Pharmacology and D.Sc. in Science. He is currently Founder and CEO of Collaborations Pharmaceuticals, Inc. which is focused on using machine learning approaches for rare and neglected disease drug discovery.
Denis Fourches, PhD
Development and application of cheminformatics methods to characterize, visualize, model and predict dynamic protein-ligand interactions. We focus on kinase-inhibitor complexes (cancer treatment) and HLA-drug complexes (adverse drug reactions).
Clark Jeffries’s research focuses on design and interpretation of assays of small RNAs as agents of signaling that may be causally upstream of many other types of biomarkers.
Dr. Jian Jin is an internationally recognized medicinal chemist with more than 20 years of experience in small-molecule drug discovery. He is currently the Mount Sinai Endowed Professor in Therapeutics Discovery, a Professor in Departments of Pharmacological Sciences and Oncological Sciences, and the Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at Mount Sinai. Dr. Jin’s laboratory is a leader in discovering selective inhibitors of histone methyltransferases and biased ligands of G protein-coupled receptors, and a pioneer in developing novel degraders targeting oncogenic proteins. Dr. Jian Jin received a Bachelor’s of Science degree in chemistry from University of Science and Technology of China in 1991 and a PhD in organic chemistry from the Pennsylvania State University in 1997. After completing a post-doctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC) as an Associate Professor. He had also served as an Associate Director of Medicinal Chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Dr. Jin was recruited to Icahn School of Medicine at Mount Sinai as a professor with tenure in 2014. Dr. Jin has published >150 peer-reviewed papers and delivered >100 invited talks. He is also an inventor of >50 issued U.S. patents and published PCT patent applications.
Dr. John’s is the Director of Medicinal Chemistry, GlaxoSmithKline and was awarded the “Hero of Chemistry” award from the American Chemical Society for his work in creating the drug Tivicay (dolutegravir), which is now widely used worldwide to treat HIV infection. He is now leading the GSK team that is collaborating with the UNC-Chapel Hill HIV Cure Center. That research is focused on creating a drug that will cure HIV, not just suppress the symptoms.
Kyoko Nakagawa-Goto received her Ph.D. in Pharmaceutical Science with an emphasis in chemistry from the Graduate School of Natural Science & Technology at Kanazawa University in Japan. She worked as an Assistant Professor in the same university until 1998.
Dave Nichols’ D1 agonists is currently in clinical trials in schizophrenia patients to determine whether a D1 agonist can improve working memory and cognition. His general interests continue in the medicinal chemistry and pharmacology of CNS-active agents.
Lars Pedersen, Ph.D.
Adjunct Associate Professor, UNC Eshelman School of Pharmacy
Staff Scientist, Head of Collaborative Crystallography Lab, NIEHS[/column]
Dr. Tang is a collaborating member from ViiV Healthcare with the UNC-Chapel Hill HIV Cure Center. His research is focused on discovering novel HIV latency reversal agents with better tolerability and exploring new ways to clear the latent T cells upon activation and viral particles.
Dr. Lan Xie has more than 35 years of experience in the field of medicinal chemistry. Her research focuses on discovery and development of new anti-HIV and antitumor drugs, including design, synthesis, lead optimization, and druggability assessments.
Dr. Zheng is an Associate Professor & the Assistant Chair of Department of Pharmaceutical Sciences and a principle investigator of the BRITE Institute at North Carolina Central University. His lab focuses on the development and application of Computer Aided Drug Design (CADD) Tools to various drug discovery projects. He is also developing and applying artificial intelligence (AI) technologies to pharmaceutical data analysis for drug repurposing in cancer, neurodegenerative and rare diseases.